Literature DB >> 12097563

Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins.

Karl Haglund1, Ingrid Leiner, Kristen Kerksiek, Linda Buonocore, Eric Pamer, John K Rose.   

Abstract

We investigated long-term memory and recall cellular immune responses to human immunodeficiency virus type 1 (HIV-1) Env and Gag proteins elicited by recombinant vesicular stomatitis viruses (VSVs) expressing Env and Gag. More than 7 months after a single vaccination with VSV-Env, approximately 6% of CD8(+) splenocytes stained with major histocompatibility complex class I tetramers containing the Env p18-I10 immunodominant peptide and showed a memory phenotype (CD44(Hi)). The level of tetramer-positive cells in memory was about 14% of the peak primary response. Recall responses elicited in these mice 5 days after boosting with a heterologous recombinant vaccinia virus expressing HIV-1 Env showed that 40 to 45% of CD8(+) splenocytes were tetramer positive and activated (CD62L(Lo)), and these cells produced gamma interferon after stimulation with Env peptide, indicating that they were functional. Five months after the boost, the long-term memory cell population (tetramer positive, CD44(Hi)) constituted 30% of the CD8(+) splenocytes. Recall responses to HIV-1 Gag were examined in mice primed with VSV recombinants expressing HIV-1 Gag protein and boosted with a vaccinia virus recombinant expressing Gag. Using this protocol, we found that approximately 40% of CD8(+) splenocytes were activated (CD62L(Lo)) and specific for a Gag immunodominant peptide (tetramer positive). The high-level Gag recall response elicited by the vaccinia virus-Gag was greater than that obtained by boosting with a VSV-Gag vector with a different VSV glycoprotein. The corresponding levels of CD44(Hi) memory cells were also higher long after boosting with vaccinia virus-Gag than after boosting with a glycoprotein exchange VSV-Gag. Our results show that VSV vectors elicit high-level memory CTL responses and that these can be amplified as much as six- to sevenfold using a heterologous boosting vector.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12097563      PMCID: PMC136360          DOI: 10.1128/jvi.76.15.7506-7517.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Activated and memory CD8+ T cells can be distinguished by their cytokine profiles and phenotypic markers.

Authors:  M K Slifka; J L Whitton
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

2.  Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory.

Authors:  D Homann; L Teyton; M B Oldstone
Journal:  Nat Med       Date:  2001-08       Impact factor: 53.440

3.  An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

Authors:  N F Rose; P A Marx; A Luckay; D F Nixon; W J Moretto; S M Donahoe; D Montefiori; A Roberts; L Buonocore; J K Rose
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

4.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

5.  Direct analysis of the dynamics of the intestinal mucosa CD8 T cell response to systemic virus infection.

Authors:  D Masopust; J Jiang; H Shen; L Lefrançois
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

6.  Down-regulation of homing receptors after T cell activation.

Authors:  T M Jung; W M Gallatin; I L Weissman; M O Dailey
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

7.  Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection.

Authors:  M R Betts; D R Ambrozak; D C Douek; S Bonhoeffer; J M Brenchley; J P Casazza; R A Koup; L J Picker
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

8.  Direct ex vivo kinetic and phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization.

Authors:  D E Hassett; M K Slifka; J Zhang; J L Whitton
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

9.  Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.

Authors:  D C Montefiori; J T Safrit; S L Lydy; A P Barry; M Bilska; H T Vo; M Klein; J Tartaglia; H L Robinson; B Rovinski
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

10.  Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.

Authors:  N F Rose; A Roberts; L Buonocore; J K Rose
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

View more
  34 in total

1.  Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses.

Authors:  Sima Velashjerdi Farahani; Mohammad Reza Aghasadeghi; Arash Memarnejadian; Sobhan Faezi; Zahra Shahosseini; Mehdi Mahdavi
Journal:  Pathog Glob Health       Date:  2016-04-13       Impact factor: 2.894

2.  Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.

Authors:  John B Schell; Nina F Rose; Kapil Bahl; Kathryn Diller; Linda Buonocore; Meredith Hunter; Preston A Marx; Ratish Gambhira; Haili Tang; David C Montefiori; Welkin E Johnson; John K Rose
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

3.  Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo.

Authors:  Bruno Garulli; Maria G Stillitano; Vincenzo Barnaba; Maria R Castrucci
Journal:  Clin Vaccine Immunol       Date:  2008-08-27

4.  Comparison of multiple vaccine vectors in a single heterologous prime-boost trial.

Authors:  Brice Barefoot; Natalie J Thornburg; Daniel H Barouch; Jae-Sung Yu; Christopher Sample; Robert E Johnston; Hua Xin Liao; Thomas B Kepler; Barton F Haynes; Elizabeth Ramsburg
Journal:  Vaccine       Date:  2008-09-20       Impact factor: 3.641

5.  A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals.

Authors:  Elizabeth Ramsburg; Jean Publicover; Linda Buonocore; Amanda Poholek; Michael Robek; Amy Palin; John K Rose
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease.

Authors:  Jon D Reuter; Beatriz E Vivas-Gonzalez; Daniel Gomez; Jean H Wilson; Janet L Brandsma; Heather L Greenstone; John K Rose; Anjeanette Roberts
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.

Authors:  James P McGettigan; Kristin Naper; Jan Orenstein; Martin Koser; Philip M McKenna; Matthias J Schnell
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 8.  Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.

Authors:  Kwang-Chul Kwon; Dheeraj Verma; Nameirakpam D Singh; Roland Herzog; Henry Daniell
Journal:  Adv Drug Deliv Rev       Date:  2012-10-23       Impact factor: 15.470

Review 9.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.